Roche Holding (RHHBY)
(Delayed Data from OTC)
$38.84 USD
-0.07 (-0.18%)
Updated Aug 1, 2025 03:59 PM ET
3-Hold of 5 3
C Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RHHBY 38.84 -0.07(-0.18%)
Will RHHBY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RHHBY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RHHBY
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
RHHBY: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues
Other News for RHHBY
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Trump Trade: Trump signs executive order raising tariff on Canada to 35%
Roche's Susvimo maintains vision over five years with two refills per year in people with ...
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With ...
Roche announces data from Phase 3 Portal study of Susvimo